Luke Sergott

how much is you are being pulled forward on these investments and how that kind of shakes out? Just trying to think about from exit rate margin opportunity

where are you looking to deploy that R&D? Know, where are the new high-growth areas that you guys would like to be bigger in

So I just kind of wanted to talk about the backlog here, and the DSA bookings are starting to ramp, continued strength there

And kind of related to that, and this kind of the overall with the AI fears based within the market and particularly within your business

Is that still in line with what you had done in the past, like, let's say, like 3 to 6 months

talk about appetite here from an inorganic sense on bolt-on versus on more strategic

can you just give a sense of what the underlying growth drivers are as you think about, or the assumptions on the growth drivers

how are you guys thinking about 1Q and then how that ramps throughout the year?

what kind of tests are what's being marketed -- and what kind of tests you guys are going to be driving through there?

When you kind of break it down on a test per day, it's roughly flattish to what you guys had last year

anything that you can dig in on from like a therapy indication? We've been hearing a lot about metabolic disease from the other CROs

how they're thinking about the tariff and if there's you think that there's more pipeline rationalization or R&D cuts

if you could talk about, like, how the recent M&A contributes, maybe some of the tariffs or tariff offsets, you know, the core improvements

How much of this is due to the middle market strategy within the PI business

Can you just kind of double-click in there and give us a sense of what's going on and your outlook

how are you guys thinking about when that funding starts coming back? And where in that cycle would you guys start to see some of the pickup

how is that kind of playing out when you're thinking about baked into that guide and how the pacing has been through the quarter and into 4Q

Can you just kind of give us a breakdown of how you're looking at that by segment, particularly around the industrial side and what you're seeing there from PID and core industrial

Can you give us a sense of like how overaged the active installed base is given all the uncertainty led to some pushouts

4Q margin. For -- Yes, for this year from 3Q

Can you talk a little bit more about the cohesion that you're trying to build in there

Just give us a look at, like, what the backlog looks like or where the demand is

Does that have anything to do with kind of what peers are talking about from potential increasing of DRG or VBP plans over there to get into cancer or oncology testing?

is this essentially you guys looking at it and saying, all right, well, this is a tougher environment. We can kind of pull forward some of those cost actions

Just kind of the puts and takes of what's going on. I assume that there's probably a little bit of volume there

Just talk about the various dynamics that you're seeing there and kind of the outlook for repro for the year?

are the investments that you're taking now, does that kind of in the shifting the manufacturing, is that potential, put any pressure or inability to hit those longer-term margin targets?

your guide seems really conservative and just kind of straight lining what you're seeing now out further. So from a downside perspective or what do you think that could derail that momentum

Any kind of color on when you started to see that demand turn because you guys have a pretty short-cycle business?

given what we've seen from the larger peers right now on the downstream side and issues with resins and pushouts.

given that you guys have like a pristine balance sheet right now, producing a lot of cash margins going the right way